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Abstract
Background: Currently, a PET-CT is used to assess the need for extended field radiotherapy of para-aortic lymph nodes
(PALN) in International Federation of Gynaecology and Obstetrics (FIGO) stage IB2, IIA2–IVA (locally advanced
stage) cervical cancer. A small study established a sensitivity and specificity estimate for PALN metastases of
50% (95% CI; 7–93%) and 83% (95% CI; 52–98%), respectively. Surgical staging of PALN may lead to a higher
diagnostic accuracy. However, surgical staging of para-aortic lymph nodes in locally advanced stage cervical
cancer is not common practice. Therefore, a phase 2 randomised controlled trial is needed to assess its safety
and feasibility.
Methods/design: In addition to standard imaging (MRI or CT scan) with PET-CT, 30 adult women with FIGO stage IB2,
IIA2–IVA cervical cancer will be randomised to receive either surgical staging or usual PET-CT staging. Administering
extended field radiotherapy will be based on lymphadenectomy results for the intervention group and on the PET-CT
results for the control group. Follow-up visits at 0, 3, 6, 9 and 12 months will assess health-related quality of life and
progression-free survival.
Primary safety and feasibility outcomes of surgical staging will be assessed by calculating means with 95% confidence
intervals for duration of surgery, number of complications, blood loss, nodal yield after para-aortic lymphadenectomy
and treatment delay due to surgical staging. Secondary patient-centred outcomes on quality of life and first
year survival will be documented and compared between the two groups. Estimates of sensitivity, specificity
and negative and positive predictive values of MRI, PET-CT and surgical staging will be presented with 95%
CI.. All analysis will be performed according to the intention to treat principle.
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Discussion: This study will assess safety and feasibility, expressed as the number and severity of complications, effect
on quality of life and the treatment delay due to surgically staging para-aortic lymph nodes in locally advanced cervical
cancer. It will provide insight in the diagnostic accuracy of the PET-CT and detection rate of missed (micro)metastases
due to surgical staging. This information will be used to assess the necessity for a phase 3 study on the diagnostic
accuracy of the PET-CT and surgical staging. If a phase 3 study is deemed necessary, current data can be used for
sample size calculation of such a phase 3 study.
Trial registration: Nederlands Trial Register/Dutch Trial Registry (www.trialregister.nl), NTR4922. Registered on 24
November 2014.
Keywords: Diagnostic accuracy, PET-CT, Advanced stage cervical cancer, Para-aortic lymph node metastases, Para-
aortic lymphadenectomy, Safety, Feasibility, Surgical staging
Background
Cervical cancer is fairly rare in the Netherlands, with an
incidence of approximately 700 new diagnoses each year
or approximately 8.3 new diagnoses per 100,000 women
per year in the Netherlands [1]. Staging is based on the
International Federation of Gynaecology and Obstetrics
(FIGO) staging system for cervical cancer. It uses clinical
features and becomes increasingly inaccurate as the dis-
ease progresses, with accurate staging failure rates rising
from 25% in FIGO stage I and II to 65–90% in stage IIIB
[2]. The lymph node status of pelvic and para-aortic
lymph nodes is, besides tumour stage, the most important
prognostic factor for disease recurrence in cervical cancer
[3]. Failure to detect metastases in these lymph nodes may
lead to suboptimal treatment. Para-aortic lymph node
(PALN) metastases are quite common in FIGO IIA
patients with positive pelvic lymph nodes (16%), whereas
solitary PALN are rare (0.8%) [4]. PALN metastases affect
around 20% of all stage IB2–IVA, although other studies
claim considerably higher rates up to 40% [4–7].
Patients with advanced stage cervical cancer (FIGO
stage IB2, IIA2–IVA) are primarily treated with pelvic
radiotherapy and concomitant chemotherapy. Para-
aortic lymph node (PALN) status and a subsequent need
for extended field radiotherapy is assessed using a posi-
tron emission tomography (PET) combined with com-
puted tomography (CT) scan (PET-CT). PET-CT
provides a higher sensitivity and specificity than mag-
netic resonance imaging (MRI) [8, 9]. However, for
detecting PALN metastasis, PET-CT seems to have a
sensitivity and specificity of 50% (95% CI; 7–93%) and
83% (95% CI; 52–98%), respectively [10]. This uncer-
tainty and these broad confidence intervals are due to
the fact that only one small study (n = 16) explicitly
assessed the diagnostic accuracy of the PET-CT. So far,
this study is the only study that compared the PET-CT
results of para-aortic lymph nodes in cervical cancer to
the gold standard of histology. More evidence on
diagnostic accuracy of PET-CT in detecting PALN me-
tastases is needed. Some intervention studies provide a
part of these data as they include surgical staging and
the PET-CT in advanced stage cervical cancer, such as
the LILACS trial [11]. However, in the LILACS trial, sur-
gical staging is only performed in PET-CT negative pa-
tients and not in PET-CT positive patients. This may be
due to the fact that the PET-CT seems to have a sensi-
tivity of 50% and specificity of 83%, thus possibly being
false negative in half of all patients with PALN metasta-
ses while being false positive in 17% of all patients with-
out PALN metastases, or due to the assumption that the
specificity and positive predictive value of the PET-CT
are already acceptable. Regardless, although missing a
PALN metastases due to a false negative result may be
more detrimental to survival than ‘overtreating’ patients
due to a false positive result, the radiotherapy-induced
complications can also have a negative impact on the
quality of life of patients. In addition, the confidence
interval surrounding the specificity of the PET-CT
ranges from 52 to 98%, leading to a large uncertainty. As
such, more evidence on both the sensitivity and specifi-
city of the PET-CT is warranted..
Recent studies show that surgical staging not only vali-
dates the imaging results, but may also lead to a treat-
ment modification in 20–40% of the patients with locally
advanced cervical cancer compared to PET-CT results
[2, 12–16]. Surgical staging, i.e. removing the para-aortic
lymph nodes by performing a para-aortic lymphadenec-
tomy, leads to a gain in diagnostic accuracy by allowing
adequate histological evaluation of the retrieved lymph
nodes. Additionally, the resection of enlarged positive
lymph nodes may provide therapeutic benefit [2, 15–18].
Whether this is due to removing the bulk of the disease
or ensuring the radiation field includes confirmed nodal
disease, or both, is unclear.
The proportion of treatment modifications may de-
pend on both the diagnostic accuracy of the PET-CT
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and a clinician’s experience with interpreting the PET-
CT results and performing the surgical staging. The val-
idity of detecting metastasis with surgical staging com-
pared to standard diagnostics remains to be elucidated.
Currently, PET-CT is the gold standard in the Netherlands
when there is a suspicion of para-aortic lymph node metas-
tases based on either clinical data, MRI or CT scan. In
addition, surgical staging of PALN in locally advanced stage
cervical cancer is not common practice. Therefore, a phase
2 trial to assess safety and feasibility is warranted.
The PALDISC (Para-Aortic Lymphadenectomy In
advanced stage Cervical cancer) trial will assess safety
and feasibility of surgical staging in locally advanced cer-
vical cancer in the Netherlands. It will provide insight in
diagnostic accuracy of the PET-CT and detection rate of
missed (micro)metastases due to surgical staging. This
information will be used to assess the necessity for a
phase 3 study on the diagnostic accuracy of the PET-CT
and surgical staging. If a phase 3 study is deemed neces-
sary, current data can be used for the sample size calcu-
lations of such a phase 3 study.
Methods/design
This study is a multi-centre randomised controlled phase
2 trial with 1 year of follow-up. The study is currently
being conducted at the Radboudumc Nijmegen and Cath-
arina Hospital Eindhoven in the Netherlands. A general
overview of the study is presented in a SPIRIT flow
diagram (Fig. 1).
Inclusion criteria
Women (aged ≥ 18 years) with FIGO IB2, IIA2, IIB, IIIA,
IIIB and IVA cervical cancer from general and specia-
lised hospitals for gynaecologic care in the Netherlands
are eligible for randomization after meeting the follow-
ing criteria:
1. Age of 18 years or above;
2. Histologically confirmed squamous cell,
adenosquamous or adenocarcinoma of the cervix;
3. FIGO stage IB2, IIA2, IIB, IIIA, IIIB and IVA,
staging performed by examination under
anaesthesia;
4. Fit for surgery;
5. WHO-performance 0-2;
6. WBC > 3.0 × 109/L, platelets > 100 × 109/L,
creatinine clearance > 60 ml/min;
7. Chest CT or X-ray, abdominal MRI or CT scan and
PET-CT with no evidence of distant metastasis (PET
positive > 2 cm);
8. Written informed consent.
Exclusion criteria
A potential subject who meets any of the following
criteria will be excluded from participation in this
study:
– Previous malignancy (except for non-melanoma skin
cancer)
– Prior retroperitoneal surgery
– Previous pelvic or abdominal radiotherapy
– Upper abdominal intraperitoneal disease or evidence
of ovarian metastasis
– Evidence of distant metastasis on imaging or
physical examination
– Bulky para-aortic lymph nodes > 2 cm
– Pregnancy
– Otherwise unfit for surgery
Fig. 1 SPIRIT flow diagram
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Randomisation, blinding and treatment allocation
After providing informed consent, all patients will be rando-
mised by the enrolling clinician using the randomization pro-
gram provided by Castor EDC. Patients will be randomised
equally between surgical staging and standard treatment
using a permuted block design per centre; the allocation
sequence itself is concealed from the patient, investigator
and clinician [19]. Blinding of the patient, investigator and/or
observer from the allocation result is not possible.
Intervention, surgical procedure and histological analysis
Figure 2 shows the patient flow. Patients in the interven-
tion arm will receive surgical staging of PALN, besides
the regular treatment and imaging (including PET-CT)
of locally advanced stage cervical cancer. This will be a
laparotomic, laparoscopic or robot-assisted node by
node para-aortic lymphadenectomy from the common
iliac bifurcation up to the left renal vein, performed by
an experienced team of retroperitoneal surgeons. In case
of a laparoscopic or robotic procedure, the surgeon may
choose between trans- or peritoneal approach. All open
procedures should be based on a retroperitoneal approach
due to reported increased morbidity [15, 20–22]. A senti-
nel node procedure, as well as a debulking of bulky pelvic
nodes, and an ovarian displacement to avoid radiotherapy
on an ovary may be performed optionally.
Histological analysis of PALN will be performed node
by node and includes all normal procedures with an add-
itional assessment on lymph node yield, node diameter
and diameter of micro metastases. Patients with meta-
static PALN on histological analysis will receive extended
field radiation therapy with concurrent chemotherapy and
optional adjuvant chemotherapy. To ensure a comprehen-
sive assessment of the primary tumour, nodal sites and
potential metastatic sites, a physical examination including
a rectovaginal examination under anaesthesia and radi-
ology including a chest CT or X-ray, abdominal MRI and
PET-CT scan are performed. All PET-CT-detected para-
stage cervical cancer
Informed consent 
& 
Randomisation
Standard diagnostics
With
Initial treatment plan i.e. chemo 
radiation
Chemo radiation as planned
QoL, Morbidity and Mortality
Standard diagnostics
With
Initial treatment plan i.e. chemo 
radiation
Neo adjuvant surgical resection of 
PALN
Chemo radiation based on 
histological outcomes
Surgical outcomes
Proportion changed treatment 
plans
QoL, Morbidity and Mortality
Fig. 2 Patient flow
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aortic lymph nodes will be described and registered per
region. In the surgical staging group, all PALNs will be
excised, described and registered per region in order to
correlate radiological, surgical and histological findings.
Control group
Patients in the control group will receive treatment
according to the current guidelines, i.e. treatment with
regards to PALN status will be based on PET-CT.
Radiotherapy and adjuvant chemotherapy
All patients will be treated with both external beam
radiotherapy (EBRT) and brachytherapy. The choice for
applying extended field radiotherapy will be based on
surgical staging or PET-CT, according to the results of
the study arm. Concomitant chemotherapy will consist
of 5 cycles of weekly cisplatin (40 mg/m2), coinciding
the first dose of chemotherapy with the first dose of
radiotherapy.
Main study parameters and analysis
The main study parameters are the safety and feasibility
of para-aortic surgical staging. The feasibility will be
assessed by registering a proportion of included patients
amongst all eligible patients. We will assess the safety by
calculating means with 95% confidence intervals (CI) for
length of surgery, number of complications per Clavien-
Dindo category (Appendix 1), amount of blood loss and
number of adverse events which will be reported using
the Serious Adverse Event Report (SAE) form (Appendix
2) [23]. Also, mean nodal yield with 95% CI after para-
aortic lymphadenectomy will be presented and com-
pared to results found in other studies in order to assess
completeness of lymphadenectomy.
Secondary study parameters and analysis
Although this is a phase 2 trial, we will also register sec-
ondary outcome parameters such as (progression-free)
survival and quality of life as they are also aspects of
safety. The incidence of advanced stage cervical cancer
is quite low in the Netherlands. Including these second-
ary parameters will make it possible to enter these pa-
tients into a subsequent phase 3 trial, if the current
PALDISC study shows that such a phase 3 study is
indeed necessary. Decision on the necessity of a phase 3
trial will depend on whether surgical staging of PALN in
advanced stage cervical cancer is deemed safe, feasible
and necessary in comparison with the performance of
current PET-CT imaging.
The proportion of changed initial treatment plans and
diameter of metastases will be documented and pre-
sented. Data on sensitivity, specificity and negative and
positive predictive values of MRI, PET-CT and surgical
staging will be documented in 2 × 2 tables; estimates will
be provided with 95% CI.
Time to treatment will be measured in days from the
day of randomization until start of chemo radiation.
Difference in treatment delay between the arms, due to
surgical intervention and histological analyses, will be
presented using a Kaplan-Meier curve with the corre-
sponding medians and 95% CI. Rate differences and 95%
CI for mortality and morbidity during follow-up will be
calculated and presented in a table.
The analysis of progression-free survival and overall
survival will be based on and presented in a Kaplan-
Meier curve with corresponding hazard ratio and 95%
CI. Means and range in reported quality of life will be
reported using the Dutch versions of the European
Organisation for Research and Treatment of Cancer
(EORTC) Core Questionnaire, the QLQ-C30 version 3.0
and the supplemental cervical cancer-specific module,
the QLQ-CX24 [24, 25]. The difference in quality of life
between the arms will be presented as a mean difference
with 95% CI.
Data entry, missing data, loss to follow-up and withdrawal
All data will be analysed on an intention to treat basis.
Data entry, coding, security and storage are planned and
provided within Castor EDC, including data quality
checks such as checks on double data entry, range checks
for data values, etc. [19].
Missing data will be imputed with multiple imputation
if assumed to be missing at random. Patients lost to
follow-up or dropping out will not be replaced for it might
indicate problems in feasibility.
Subjects can leave the study at any time for any reason if
they wish to do so without any consequences. The reason
will be documented on the case report form. Patients who
have withdrawn themselves from the study will receive
treatment and follow-up according to national protocol.
Sample size calculation, data monitoring and premature
termination of the study
We will include 15 patients in each arm for this phase II
study. There will be no formal data-safety monitoring board
due to the relatively small number of patients (n = 15) in
the intervention arm. However, due to the nature of this
intervention and possible risk related to the intervention,
we have installed an independent expert to ensure the
safety and ethics. After each serious adverse event, which
may in any way be related to the para-aortic lymphadenec-
tomy, all inclusions and planned interventions at all centres
will be stopped immediately. All principle investigators will
converge and decide whether it is ethical to resume inclu-
sion after the serious adverse event has abated or until a
stable situation has been reached. All meetings and decisions
will be documented. Each conclusion will be submitted to
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the independent expert for an independent assessment on
safety and ethics. The trial will only resume after both the
principle investigators and independent expert agree that
safety and ethical criteria are being met. An independent
monitor will check all centres on informed consent, adher-
ence to the in- and exclusion criteria, reporting of all adverse
events and full source document verification. The monitor
will audit after the first three included patients and then
yearly or after every 10 included patients.
Recruitment and consent
The rationale, design and aims of the study will be
explained to each patient along with the specific informa-
tion on the respective treatment arms. The principles of
registration and the follow-up procedure will be explained,
and patients will receive written patient information and
will have ample opportunity to ask questions. Written
informed consent of the patient is required before inclu-
sion and will be obtained by the clinician.
Risk assessment
Due to experience with the procedure and known inci-
dence and severity of complications, the risk associated
with the intervention is estimated to be moderate. Para-
aortic lymphadenectomy is new in cervical cancer but a
common procedure for gynaecological oncologists in
ovarian and endometrial cancer.
Ethical considerations
The protocol has been reviewed and approved by the
Radboud Medical-Ethical Committee (METC) on the 4th
of September 2014 with reference number: 2014/240 and
registration number: NL49310.091.14, as well as approved
by the Radboudumc Board of Directors on 21st of October
2014 with reference number: RvBI4.5 L737. (supplements
in Dutch) The study is being conducted in full conform-
ance with the ethical principles of the Declaration of
Helsinki Seoul, 2008, the WMO, the Dutch guidelines ‘rich-
tlijn toetsingsprocedure multicenter-onderzoek’ (active as
of 1 January 2001) and ‘good clinical practice’.
Public disclosure, availability of data and materials and
publication policy
Within 1 year after the end of the study, a final study
report with the results of the study will be submitted,
including any publications/abstracts of the study to the
accredited ethical committee. Publications and abstracts
will be published according to policy of the Central
Committee on Research Involving Human Subjects.
The final trial results will be submitted to a peer-
reviewed scientific journal for publishing irrespective of
the nature of the results.
Discussion
The PALDISC trial will assess safety and feasibility of
surgical staging in patients with locally advanced cervical
cancer in the Netherlands. It will provide insight in diag-
nostic accuracy of the PET-CT and detection rate of
missed (micro)metastases due to surgical staging.
So far, all available evidence regarding the validity and
diagnostic accuracy of PET-CT in detecting PALN metas-
tases in locally advanced cervical cancer is based on a
study with 16 patients only [10]. This leads to a high un-
certainty regarding both sensitivity and specificity, which
is represented by the large confidence intervals. As a
result, patients may have a high chance on false negative
and/or false positive PET-CT results, leading to subse-
quent under- and overtreatment, respectively. Undertreat-
ment may lead to a deterioration of overall and
progression-free survival, while overtreatment may lead to
unnecessary radiation. Both have detrimental effects on
the quality of life of patients as well as hospital and health
care expenses.
To compare the effectiveness and diagnostic accuracy
of a PET-CT with surgical staging, a phase 3 randomised
controlled trial is the most warranted design. However,
as para-aortic lymphadenectomy is not standard of care
for cervical cancer patients in the Netherlands, we feel
the need to first assess its safety and feasibility.
A major strength of our study is that safety and feasibil-
ity of the para-aortic lymphadenectomy is assessed on
both subjective (quality of life) and objective (time of
treatment delay, blood loss, adverse events, etc.) outcome
measures. In addition, data on both sensitivity and specifi-
city should also be considered. Although this study only
includes 15 patients, it is almost a doubling of the
currently available number of patients in whom PET-CT
was compared to gold standard histology (n = 16) [10].
Furthermore, these outcomes can be compared to current
standard of care while controlling for confounders and
selection bias due to the randomization. These strengths
will provide vital information for a group of experts in
order to make the final decision whether or not a phase 3
trial is deemed safe and necessary.
As for most surgical trials, blinding is not possible. To
preclude bias due to this lack of blinding, we have chosen
objective outcomes on safety and feasibility as the primary
outcome for this trial and the subjective quality of life as a
secondary outcome. Combining these results will provide
insight in the safety and feasibility of para-aortic lymphad-
enectomy in advanced stage cervical cancer.
Trial status
The PALDISC trial is currently cancelled, and further inclu-
sion is on hold due to a too low inclusion rate. Recruitment
began in July 2015 and a total of five patients were enrolled
by October 2017. This low inclusion rate which has led to
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the cancellation of the study is mainly due to the fact that
the incidence of advanced stage cervical cancer is low in
the Netherlands and there was only one actively participat-
ing centre. With the publication of this protocol, we do
hope to spark the interest of other centres for such a trial.
In addition, we would like to open a scientific discussion on
the diagnostic accuracy of the PET-CT as there is currently
no study that compares PET-CT positive results to gold-
standard histology analyses. The specificity of 83% (95% CI;
52–98%) based on only 16 patients implies that possibly
17% of all patients have false positive PET-CT results with-
out PALN metastases. This may lead to misinformed treat-
ment decisions including ‘unnecessary’ extended field
radiotherapy with associated comorbidities. As such, more
evidence on both the sensitivity and specificity of the PET-
CT is warranted.
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